PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
Por:
Henriquez I, Malave B, Campos F, Hidalgo E, Muelas R, Ferrer C, Munoz-Rodriguez J, Villamon A, Pascual M, Badia J, Fuertes J, Hinojosa-Salas P
Publicada:
1 feb 2025
Ahead of Print:
1 jul 2024
Resumen:
|